About Fluzone Intradermal Vaccine
Fluzone Intradermal vaccine, the only FDA-approved intradermal flu vaccine in
the United States
, is an inactivated influenza virus vaccine given to people 18 through 64 years of age for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
The Fluzone Intradermal vaccine needle is an ultra-thin microneedle that is 90 percent smaller and only goes as deep as the skin's surface to help protect against the flu. Smaller than a grain of rice, the microneedle is only 1.5mm long, which is about the same as the thickness of a U.S. penny.
To find out where Fluzone Intradermal vaccine is available in your area, or to learn more about Fluzone Intradermal vaccine, visit
Redness, firmness, swelling, and itching at the injection site occur more frequently with Fluzone Intradermal vaccine than with Fluzone vaccine. Other common side effects to Fluzone Intradermal vaccine include pain at the injection site, headache, fatigue, and muscle aches. Side effects other than those listed above may occur. Fluzone Intradermal vaccine should not be administered to anyone with a severe allergic reaction to any vaccine component, including eggs, egg products, or to a previous dose of any influenza vaccine. Tell the doctor if you have ever experienced Guillain-Barré syndrome (severe muscle weakness) after a previous dose of influenza vaccine. If you notice any other problems or symptoms following vaccination, please contact your health care professional immediately. Vaccination with Fluzone Intradermal vaccine may not protect all individuals.
For more information about Fluzone Intradermal vaccine, talk to your health care professional and see complete Patient Information.
About The Survey
The national survey results are from GfK Roper's weekly telephone omnibus service, OmniTel. Interviewing was conducted from
June 1-3, 2012
. A total of 1005 interviews with adults aged 18+ were completed, with 663 among the target subgroup of adults aged 18 through 64. The margin of error for this study is +/- 3 percentage points for total sample and is higher for subgroups.
Localized survey results are from GfK Roper's weekly telephone omnibus service, OmniTel. Interviewing was conducted from
August 29 - September 3, 2012
. A total of approximately 400 interviews with adults 18 through 64 years of age were completed in five cities,
, for a total of approximately 2000 interviews. The margin of error for this study is +/- 4 percentage points for each city sample of approximately 400 and is higher for subgroups.
All above surveys were sponsored by Sanofi Pasteur, the vaccines division of Sanofi.